MARKET

APLS

APLS

Apellis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.46
-0.14
-0.29%
After Hours: 47.46 0 0.00% 16:07 11/25 EST
OPEN
47.78
PREV CLOSE
47.60
HIGH
47.97
LOW
46.32
VOLUME
399.34K
TURNOVER
--
52 WEEK HIGH
49.42
52 WEEK LOW
16.85
MARKET CAP
3.59B
P/E (TTM)
-5.7141
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 1d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 2d ago
Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $67
Citigroup maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $53 to $67.
Benzinga · 3d ago
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.
Zacks · 5d ago
Dosing underway for Apellis, Sobi's study of pegcetacoplan in muscle weakness
Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) having commenced dosing of the first patients in registrational Phase 2 MERIDIAN study of pegcetacoplan in ~200 adults with sporadic amyotrophic lateral sclerosis ((ALS)), a
Seekingalpha · 11/19 12:50
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) --  Apellis
Benzinga · 11/19 11:45
Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag
The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.
Zacks · 11/17 15:07
FDA accepts Apellis' pegcetacoplan application for a rare blood disorder
Under priority review status, the FDA has accepted Apellis Pharmaceuticals' (APLS) marketing application seeking approval for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria ((PNH)), a rare blood disease in which the immune
Seekingalpha · 11/16 12:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APLS. Analyze the recent business situations of Apellis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APLS stock price target is 53.79 with a high estimate of 78.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 72.07M
% Owned: 95.16%
Shares Outstanding: 75.74M
TypeInstitutionsShares
Increased
48
3.69M
New
38
-136.94K
Decreased
49
3.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Gerald Chan
President/Chief Executive Officer/Co-Founder/Director
Cedric Francois
Co-Founder/Chief Operating Officer
Pascal Deschatelets
Chief Financial Officer/Treasurer
Timothy Sullivan
Senior Vice President
Victoria Brown
Senior Vice President
Thomas Lackner
Vice President - Finance/Primary Contact
Nicole Perry
Vice President/General Counsel
David Watson
Other
Federico Grossi
Director
Stephanie OBrien
Other
Lukas Scheibler
Other
Adam Townsend
Independent Director
A. Sinclair Dunlop
Independent Director
Sinclair Dunlop
Independent Director
Paul Fonteyne
Independent Director
Alec Machiels
Independent Director
Stephanie O'Brien
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APLS
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Apellis Pharmaceuticals Inc stock information, including NASDAQ:APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.